Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
U.S. merger review is becoming a difficult “balancing act,” and there is increasing skepticism among regulators about whether “remedies” — i.e., divestitures required for big mergers — do enough to maintain a competitive market, a Justice Department official said June 20.
Regulators are coping with a rise in large, complex deals and increased concentration in many industries. That means that the traditional ways of “fixing” big mergers, by asking for behavioral changes or sales of parts of their businesses, could be less effective than in the past.
In the current environment, antitrust regulators are increasingly asking themselves whether deals that raise competition concerns are worth fixing, according to Patricia Brink, director of civil enforcement at the DOJ’s antitrust division.
“I think there is a willingness to say that the very complex remedies may not be worth it, and maybe we should just block the deal,” Brink said at a conference hosted by the American Antitrust Institute, a competition advocacy group in Washington. Brink added that she was speaking in her own capacity.
The DOJ and the Federal Trade Commission have faced a wave of mega-mergers over the last few years. The antitrust agencies took an aggressive approach toward the end of the Obama administration, blocking deals such as Halliburton Co.’s proposed acquisition of rival oil-services firm Baker Hughes Inc.
Brink said Halliburton-Baker Hughes clearly wasn’t fixable, but other cases aren’t as straightforward and require more thought. Virtually all of Halliburton’s revenues (90 percent) “derived from products also sold by Baker Hughes,” she said.
The Justice Department recently cleared a proposed tie-up of Dow Chemical Co. and Dupont Co., which will create a global chemicals giant. The parties plan to split the merged company into three companies within 18 months of closing. Even so, that deal required substantial divestitures of the companies’ herbicide and pesticide products and two types of plastics.
Whether the agencies will be more or less receptive to negotiating remedies under President Donald Trump remains uncertain, according to Richard Feinstein, an antitrust partner at Boies Schiller Flexner LLP. “I wouldn’t necessarily assume a sea change,” he said at the AAI event.
Pending deals for regulators include Walgreens Boots Alliance Inc.’s proposed takeover of Rite Aid Corp. and Bayer AG’s bid for Monsanto Co.
The FTC released a study in February concluding that the vast majority of its remedies between 2006 and 2012 were successful. But critics say remedy failures in more recent cases, such as Dollar Tree’s takeover of Family Dollar Stores Inc. in 2015, raise questions about whether such efforts can work now.
In that case, Dollar Express LLC accused rival Dollar Tree Inc. of scheming to drive it out of business despite a U.S.-approved divestiture plan to maintain a competitive discount-store retail market. Dollar Express was the recipient of divestitures from that merger, but the company now is closing some 300 stores that it claims is a result of Dollar Tree’s unfair competition practices, according to Bloomberg News.
The issue is also front and center in the Walgreens-Rite Aid deal, as questions loom about whether Fred’s Inc. is capable of buying the stores that the merged entity would be required to sell.
“It’s everyone’s hope that merger remedy policy is not being used as an indirect method of avoiding the hard decisions about challenging mergers,” John Kwoka, an economics professor at Northeastern University, said at the event.
To contact the reporter on this story: Alexei Alexis in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Fawn Johnson at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)